NASDAQ:WVE Wave Life Sciences (WVE) Stock Price, News & Analysis $5.68 -0.26 (-4.38%) (As of 09/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Wave Life Sciences Stock (NASDAQ:WVE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$5.68▼$6.0250-Day Range$5.12▼$6.6152-Week Range$3.50▼$7.67Volume1.78 million shsAverage Volume809,961 shsMarket Capitalization$708.52 millionP/E RatioN/ADividend YieldN/APrice Target$12.50Consensus RatingModerate Buy Company OverviewWave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.Read More… The election trade you can't lose (Ad)Politics is an unpredictable game. But no matter what happens in the next few months... There's one thing that can't be stopped by anything: Dividends.Download my Dividend Calendar here Wave Life Sciences Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 89th PercentileWave Life Sciences scored higher than 89% of companies evaluated by MarketBeat, and ranked 135th out of 1,006 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingWave Life Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageWave Life Sciences has only been the subject of 4 research reports in the past 90 days.Read more about Wave Life Sciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Wave Life Sciences are expected to decrease in the coming year, from ($1.04) to ($1.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Wave Life Sciences is -10.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Wave Life Sciences is -10.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioWave Life Sciences has a P/B Ratio of 14.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Wave Life Sciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.71% of the outstanding shares of Wave Life Sciences have been sold short.Short Interest Ratio / Days to CoverWave Life Sciences has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Wave Life Sciences has recently increased by 0.90%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldWave Life Sciences does not currently pay a dividend.Dividend GrowthWave Life Sciences does not have a long track record of dividend growth. Sustainability and ESG4.8 / 5Environmental Score-0.58 Percentage of Shares Shorted2.71% of the outstanding shares of Wave Life Sciences have been sold short.Short Interest Ratio / Days to CoverWave Life Sciences has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Wave Life Sciences has recently increased by 0.90%, indicating that investor sentiment is decreasing. News and Social Media1.9 / 5News Sentiment0.38 News SentimentWave Life Sciences has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Wave Life Sciences this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for WVE on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Wave Life Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Wave Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $279,555.00 in company stock.Percentage Held by Insiders29.10% of the stock of Wave Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.73% of the stock of Wave Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Wave Life Sciences' insider trading history. WVE Stock News HeadlinesWave Life Sciences Ltd. (NASDAQ:WVE) CEO Sells $279,555.48 in StockAugust 24, 2024 | insidertrades.comWave Life Sciences (NASDAQ:WVE) Trading Down 3.7%September 20 at 7:46 AM | americanbankingnews.comNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …September 20, 2024 | Weiss Ratings (Ad)Wave Life Sciences (NASDAQ:WVE) Receives New Coverage from Analysts at B. RileySeptember 20 at 6:46 AM | americanbankingnews.comB. Riley Securities Initiates Coverage of Wave Life Sciences (WVE) with Buy RecommendationSeptember 20 at 3:58 AM | msn.comCopilot Wave 2 supercharges productivity with AI across all your Microsoft 365 appsSeptember 16, 2024 | msn.comAnalysts Set Wave Life Sciences Ltd. (NASDAQ:WVE) PT at $13.17September 12, 2024 | americanbankingnews.comBuy Rating Affirmed for Wave Life Sciences with Promising Clinical Data and Upcoming MilestonesSeptember 11, 2024 | markets.businessinsider.comSee More Headlines WVE Stock Analysis - Frequently Asked Questions How have WVE shares performed this year? Wave Life Sciences' stock was trading at $5.05 at the start of the year. Since then, WVE stock has increased by 12.5% and is now trading at $5.68. View the best growth stocks for 2024 here. How were Wave Life Sciences' earnings last quarter? Wave Life Sciences Ltd. (NASDAQ:WVE) issued its quarterly earnings results on Thursday, August, 8th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.16) by $0.09. The company had revenue of $19.69 million for the quarter, compared to analyst estimates of $24.80 million. Wave Life Sciences had a negative trailing twelve-month return on equity of 1,395.99% and a negative net margin of 66.50%. Who are Wave Life Sciences' major shareholders? Wave Life Sciences' top institutional investors include Maverick Capital Ltd. (6.15%), M28 Capital Management LP (4.94%), Primecap Management Co. CA (2.18%) and Emerald Advisers LLC (2.04%). Insiders that own company stock include Ra Capital Management, LP, Paul Bolno, Chandra Vargeese, Kyle Moran and Chris Francis. View institutional ownership trends. How do I buy shares of Wave Life Sciences? Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Wave Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Wave Life Sciences investors own include Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), VBI Vaccines (VBIV) and Aduro Biotech (ADRO). Company Calendar Last Earnings8/08/2024Today9/20/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:WVE CUSIPN/A CIK1631574 Webwww.wavelifesciences.com Phone(656) 236-3388Fax617-949-2901Employees240Year FoundedN/APrice Target and Rating Average Stock Price Target$12.50 High Stock Price Target$19.00 Low Stock Price Target$5.00 Potential Upside/Downside+109.7%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-57,510,000.00 Net Margins-66.50% Pretax Margin-67.11% Return on Equity-1,395.99% Return on Assets-31.99% Debt Debt-to-Equity RatioN/A Current Ratio0.99 Quick Ratio0.99 Sales & Book Value Annual Sales$113.31 million Price / Sales6.56 Cash FlowN/A Price / Cash FlowN/A Book Value$0.40 per share Price / Book14.90Miscellaneous Outstanding Shares124,740,000Free Float86,835,000Market Cap$743.45 million OptionableOptionable Beta-1.13 This page (NASDAQ:WVE) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | SponsoredThe Perfect Storm for an EV RevoltWith constant talk about Artifical Intelligence, inflation, and the upcoming election clogging the airwaves......Eagle Publishing | SponsoredTrump’s “Tax Free” Retirement StrategySince 1924 — over one hundred years — the US dollar has lost nearly 18x its value. If you're planning on re...Gold Safe Exchange | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Wave Life Sciences Ltd. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Wave Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.